These benefits will be offset by the discontinuation of lower-margin FHN nutrition trading business in 2018, lower co-product sales in the other segment due to efficiency improvements and indirect tariff pressure from competition redirecting mostly technical grade products to international markets. Additionally, although we expect the impact from the timing of orders in Midwest flooding experienced in the first quarter to rebound over the next two quarters, we now expect the slowing demand that we began to see in select industrial markets in Q1 to affect our outlook for this year. As a result, as Kim Ann mentioned earlier, we are revising our revenue forecast to be 1% to 2% below 2018 revenue of $802 million to better align with the current market demands. Despite the top line reset, we are maintaining our 2019 adjusted EBITDA guidance of 1% to 3% growth compared with the prior year, with phasing in the range of 42% to 45% in half one and 55% to 58% in half two.